EyePoint Pharmaceuticals/$EYPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Ticker
$EYPT
Sector
Primary listing
Employees
165
Headquarters
Website
EYPT Metrics
BasicAdvanced
$940M
-
-$2.71
1.75
-
Price and volume
Market cap
$940M
Beta
1.75
52-week high
$14.42
52-week low
$3.91
Average daily volume
792K
Financial strength
Current ratio
7.996
Quick ratio
7.727
Long term debt to equity
8.868
Total debt to equity
9.64
Interest coverage (TTM)
-13,503.64%
Profitability
EBITDA (TTM)
-187.182
Gross margin (TTM)
-257.63%
Net profit margin (TTM)
-337.93%
Operating margin (TTM)
-364.27%
Effective tax rate (TTM)
-0.10%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-37.79%
Return on equity (TTM)
-73.95%
Valuation
Price to revenue (TTM)
17.003
Price to book
3.82
Price to tangible book (TTM)
3.88
Price to free cash flow (TTM)
-4.548
Free cash flow yield (TTM)
-21.99%
Free cash flow per share (TTM)
-2.999
Growth
Revenue change (TTM)
2.99%
Earnings per share change (TTM)
45.72%
3-year revenue growth (CAGR)
7.77%
3-year earnings per share growth (CAGR)
6.39%
What the Analysts think about EYPT
Analyst ratings (Buy, Hold, Sell) for EyePoint Pharmaceuticals stock.
Bulls say / Bears say
Shares reached a 52-week high of $14.37 on September 5, 2025, showing strong investor confidence in the company's development pipeline and upcoming data releases (CNBC turn9search0).
Cash, cash equivalents, and marketable securities totaled $371 million as of December 31, 2024, providing a financial runway through 2027 to fund ongoing clinical programs without the immediate need for external capital (SEC filing turn7search3).
Enrollment in the Phase 3 LUGANO trial for DURAVYU is over halfway complete, and the LUCIA trial is also recruiting ahead of schedule, demonstrating efficient trial execution and putting the company on track for topline data in 2026 (SEC filing turn7search3).
Q2 2025 GAAP revenue fell 44.2% year-over-year to $5.3 million, missing analyst expectations of $6.65 million, and signaling a sharp decline in legacy licensing revenues ahead of anticipated pipeline commercialization (Nasdaq.com turn4search0).
In Q4 2024, revenue was reported at $11.6 million, below analyst forecasts of $14.7 million, highlighting weak near-term commercial results and continued dependence on legacy products (SF Chronicle/AP turn5search5).
Operating expenses in Q4 2024 soared 77.6% year-over-year to $125.3 million, significantly outpacing revenue growth and raising concerns about cash burn (Google Finance turn2search0).
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
EYPT Financial Performance
Revenues and expenses
EYPT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for EyePoint Pharmaceuticals stock?
EyePoint Pharmaceuticals (EYPT) has a market cap of $940M as of September 19, 2025.
What is the P/E ratio for EyePoint Pharmaceuticals stock?
The price to earnings (P/E) ratio for EyePoint Pharmaceuticals (EYPT) stock is 0 as of September 19, 2025.
Does EyePoint Pharmaceuticals stock pay dividends?
No, EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders as of September 19, 2025.
When is the next EyePoint Pharmaceuticals dividend payment date?
EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders.
What is the beta indicator for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals (EYPT) has a beta rating of 1.75. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.